Accordingly, Llop et al. also evaluated the portion of α2–3-sialylated PSA in serum with a lectin immunoaffinity column and revealed that α2–3-sialic acid on PSA exhibited high performance in discriminating between high-risk prostate cancer patients and the benign prostate hyperplasia individuals [90]. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.